Molecular and cellular effects of in vivo chronic intravascular hemolysis and anti-inflammatory therapeutic approaches

Author(s)

Gotardo, Erica M. F. ; Brito, Pamela L. ; Gushiken, Lucas F. S. ; Chweih, Hanan ; Leonardo, Flavia C. ; Costa, Fernando F. ; Conran, Nicola

• Document type: Journal article
• Source: VASCULAR PHARMACOLOGY; v. 150, p. 12-pg., 2023-05-03.

Abstract

Intravascular hemolysis (IVH) occurs in numerous inherited and acquired disorders, including sickle cell disease (SCD), malaria and sepsis. These diseases display unique symptoms, but often share complications, such as vasomotor dysfunction and pulmonary hypertension. Consequently, in vivo models are needed to study the effects of continuous intravascular hemolytic processes, independently of the molecular alteration or extrinsic factor that leads to erythrocyte destruction. We gave twice-weekly low-dose phenylhydrazine (LDPHZ) to C57BL/6 J mice for 4 weeks, and measured parameters indicative of anemia, hemoglobin-clearance pathways, inflammation and iron turnover, comparing these to those of a murine model of SCD, which displays associated IVH. LDPHZ administration provoked discreet anemia in mice and significant reticulocytosis, in association with hemoglobin/ heme-clearance pathway protein depletion. Mice subjected to chronic hemolysis displayed elevated leukocyte counts and plasma levels of interleukin (IL)-1 beta, TNF-alpha, IL-6, soluble ICAM-1, endothelin-1 and anti-inflammatory IL-10, closely emulating alterations indicative of systemic inflammatory and endothelial activation in SCD, and confirming chronic IVH in itself as a serious complication. Discreet accelerations in hepatic and splenic iron turnover also occurred in LDPHZ mice, without alterations in liver damage markers. Examining the effects of two therapies on hemolysis-induced inflammation, the administration of hydroxyurea (and to a lesser extent, L -glutamine) significantly abrogated hemolytic inflammation in mice, without apparent inhibition of hemolysis. In conclusion, the isolation of chronic IVH, a common disease mechanism, using this model, may allow the study of hemolysis-specific sequelae at the cellular and systemic level, and the investigation of candidate agents that could potentially counter hemolytic inflammation. (AU)

• FAPESP's process: 16/10542-3 - STUDY OF PROCESSES INFLAMMATORY AND ANGIOGENIC IN A MODEL OF CHRONIC HEMOLYSIS IN VIVO AND EFFECTS OF HYDROXYUREA
• Grantee: Érica Martins Ferreira Gotardo
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 14/19173-5 - Vascular inflammation: pathophysiological mechanisms of induction and pathways of cellular activation
• Grantee: Nicola Amanda Conran Zorzetto
• Support Opportunities: Regular Research Grants